LEADERS FREE 1 year follow-up proved 1 month of ultra-short DAPT following BioFreedom™
implant was significantly safer and more efficacious than the same strategy post BMS implant.
For more information on this landmark clinical trial of a previously understudied HBR population and key subgroups click here
Spotlight BioFreedom™PCI in High Bleeding Risk
(HBR) patients The challenge for PCI in HBR patients is balancing the ischemic vs the bleeding risk associated with long-term DAPT.
BioFreedom is the only active stent with CE mark for ultra-short 1 month DAPT in High bleeding Risk (HBR) patients, supported by clinical data from a double-blind randomized controlled trial.
BioFreedom and one month of DAPT followed by SAPT alone should be the treatment strategy of choice for HBR patient undergoing PCI.
Spotlight LEADERS FREE IIFirst American Patient enrolled in the new US Pivotal BioFreedom Trial
22 March 2017 - Biosensors International Group, Ltd. announced the enrollment of the first american patient in LEADERS FREE II, its new BioFreedom Pivotal Study conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France, Germany, Italy, and the United Kingdom.